Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Accounts Receivables · Q2 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q2 FY2026 accounts receivables was $665K, compared with -$466K a year earlier. Trailing-twelve-month accounts receivables was $32.8M. Over 3 fiscal years it compounded at +39.1% a year.
Context
- Accounts receivables amounted to 48.6% of revenue in FY2025, up 47.2 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $665K or moves back toward the trailing-twelve-month quarterly average of $8.2M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 31.76M USD
- Year-over-year change
- +3164.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 31.76M | +3164.4% |
| FY2024 | 2024-09-30 | 973K | -89.7% |
| FY2023 | 2023-09-30 | 9.42M | -20.2% |
| FY2022 | 2022-09-30 | 11.8M | +148.5% |
| FY2021 | 2021-09-30 | (24.3M) | — |
Accounts Receivables vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's LTM Mar 2026 accounts receivables of $32.8M is the largest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +4000.1% is the highest of 5, against a peer median of -101.5%.
- Accounts receivables amounts to 47.4% of revenue for ENTA, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.8M | +4000.1% | +39.1% | 47.4% | |
| LTM Mar 2026 | $10.63M | — | — | 4723.1% | |
| LTM Mar 2026 | $3M | -137.5% | — | 21.6% | |
| LTM Mar 2026 | $465K | -65.5% | -17.4% | 1.3% | |
| LTM Mar 2026 | $451K | -1148.8% | +17.0% | 0.6% | |
| LTM Mar 2026 | $378K | -56.7% | -57.2% | 3.4% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ENTA) | $0 | -101.5% | -17.4% | 1.3% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (79M) | (121.76M) | (133.82M) | (116.05M) | (81.89M) |
| Depreciation & Amortization | 3.33M | 2.97M | 2.37M | 2.34M | 5.09M |
| Deferred Income Tax | 345K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.99M | 26.97M | 28.22M | 26.8M | 18.57M |
| Change in Working Capital | (13.69M) | 6.79M | 8.02M | 7.13M | 39.91M |
| Accounts Receivables | (24.3M) | 11.8M | 9.42M | 973K | 31.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.77M | (4.63M) | (1.15M) | (414K) | (1.31M) |
| Other Working Capital | 6.84M | (372K) | (243K) | 6.57M | 9.46M |
| Other Non-Cash Items | (1.98M) | 242K | (7.95M) | 1.02M | (946K) |
| Operating Cash Flow | (70M) | (84.78M) | (103.15M) | (78.76M) | (19.27M) |
| Capital Expenditures | (750K) | (2.13M) | (9.06M) | (17.95M) | (12.9M) |
| Acquisitions (Net) | (37.74M) | (54.9M) | 44.52M | 0 | 0 |
| Purchases of Investments | (307.35M) | (171.45M) | (373.39M) | (307.28M) | (209.63M) |
| Sales of Investments | 345.09M | 228.47M | 328.87M | 383.47M | 262.87M |
| Other Investing Activities | 37.74M | 54.9M | (44.52M) | 0 | 0 |
| Investing Cash Flow | 36.99M | 54.9M | (53.58M) | 58.24M | 40.35M |
| Debt Repayment | 0 | 0 | 199.68M | (27.48M) | (26.49M) |
| Common Stock Issued | 3.61M | 21.26M | 2.21M | 147K | 145K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (534K) | (1.23M) | (3.76M) | (294K) | (277K) |
| Financing Cash Flow | 3.08M | 20.03M | 198.13M | (27.63M) | (26.62M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.93M) | (9.85M) | 41.39M | (48.16M) | (5.54M) |
| Free Cash Flow | (70.75M) | (86.91M) | (112.21M) | (96.71M) | (32.17M) |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.